• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec11
Wells Fargo Analyst Maintains Biogen Hold Rating With A Price Target Of $190
04:32
Dec10
HSBC downgrades Biogen's rating and target price leading to stock price decline
13:43
Dec9
William Blair Analyst Maintains Buy Rating on Biogen
11:07
Dec8
LEQEMBI® included in China's medical insurance directory
23:51
Dec5
Stoke Therapeutics and Biogen Show Positive Data for Dravet Syndrome Drug
14:00
Dec4
Biogen CEO Purchases Company Stock
20:06

Schedules & Filings

Schedules
Filings
Oct30
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 2.535 B, Net Income 466.5 M, EPS 3.17

Jul31
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 2.646 B, Net Income 634.8 M, EPS 4.33

May1
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 2.431 B, Net Income 240.5 M, EPS 1.64

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
MSOX
7.940
+107.85%
+4.120
YCBD
1.200
+90.17%
+0.569
THH
15.520
+57.72%
+5.680
WEED
25.325
+55.65%
+9.055
NCI
1.920
+54.84%
+0.680
CNBS
34.820
+54.57%
+12.293
MSOS
5.800
+54.26%
+2.040
CGC
1.740
+53.98%
+0.610
RYM
23.800
+47.73%
+7.690
TLRY
12.150
+44.13%
+3.720
View More